课题基金 / 基金详情

Preclinical and Clinical Investigations of Severe Infection and Critical Illness

Preclinical and Clinical Investigations of Severe Infection and Critical Illness
严重感染和危重疾病的临床前和临床研究
批准号:
10923694
负责人:
ROBERT L DANNER
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
2019-nCoVAcuteAdherenceAdmission activityAdrenal Cortex HormonesAffectAldosteroneAlgorithmsAllogenicAlteplaseAnimal ModelAnimal WelfareAnti-Inflammatory AgentsAntibiotic TherapyAntibioticsAnticoagulationAortaArginineBloodBlood PlateletsBone Marrow TransplantationCOVID-19COVID-19 survivorsCanis familiarisCardiovascular DiseasesCardiovascular systemCaringCeftazidimeCell Culture SystemCellsCessation of lifeCharacteristicsChestClindamycinColistinCommunitiesComparative Effectiveness ResearchComparison armConsent FormsCounterpulsationCritical CareCritical IllnessDataDatabasesDeath RateDecision MakingDiagnosisDiagnosticDoseDrynessEarly identificationEbolaEdemaElementsEncephalitisEndotheliumEndotoxemiaEndotoxinsEpidemiologyEquilibriumEscherichia coliEtiologyFailureFibrinolysisFunctional disorderGene ExpressionGlucocorticoidsGoalsHealthcareHeartHeart InjuriesHemoglobinHeparinHistopathologyHospitalsHydrocortisoneIbuprofenIncidenceInfectionInflammationInformed ConsentInjuryInpatientsIntensive CareInterferonsInternshipsIntravenous ImmunoglobulinsInvestigationInvestmentsJournalsLeft Ventricular Ejection FractionLevaquinLiquid substanceMeasuresMeningoencephalitisMental DepressionMeta-AnalysisMineralocorticoidsModelingMorbidity - disease rateMultiple Organ FailureMusMyocardialMyocardial InfarctionNecrosisNecrotizing fasciitisNitric OxideNitric Oxide Synthetase InhibitorOrganOutcomeOutpatientsOxygenPatient SelectionPatientsPneumoniaPopulationPreventionPublic HealthPublished CommentPublishingPulmonary EmbolismRattusResearch SubjectsResistanceRiskSepsisSeptic ShockSeverity of illnessShockStaphylococcal Enterotoxin BStaphylococcal PneumoniaStem cell transplantStenotrophomonas maltophiliaStreptococcal InfectionsStreptococcusStrokeSupportive careSyndromeTherapeuticThrombusToxinToxoplasmosisTracerTransfusionTransplant RecipientsTraumaTreatment EfficacyTrimethoprim-SulfamethoxazoleVariantVascular DiseasesVasoconstrictor AgentsVentricularaerosolizedanthrax lethal factorarmattributable mortalitycardiac repaircardioprotectioncare burdenclinical investigationcomparative effectiveness trialcoronary eventdesigndrug resistant bacteriaheart functionhigh riskimprovedimproved outcomeindexinginnovationlethal factorlung injurymortalitymortality riskmouse modelnew therapeutic targetp38 Mitogen Activated Protein Kinasepandemic diseasepathogenpneumonia modelpre-clinicalprocalcitoninprophylacticreparative processresponsesenescencesevere COVID-19severe injurytigecyclinetreatment as usualtrial designvolunteer

项目摘要

项目成果

ROBERT L DANNER的其他基金

相似基金

相关文献

中文摘要
翻译
早期研究集中在感染性休克病理生理(Am J Physiol 1988; Chest 1990)、内毒素血症(J clininvest 1989; J Exp Med 1989; Chest 1991; N Engl J Med 1993; infection immune 1996)和抗内毒素治疗(Antimicrob Agents Chemother 1989; J clininvest 1987; Pharm Res 1990; JAMA 1993; J infection Dis 1994)。
英文摘要
Early studies focused on septic shock pathophysiology (Am J Physiol 1988; Chest 1990), endotoxemia (J Clin Invest 1989; J Exp Med 1989; Chest 1991; N Engl J Med 1993; Infect Immun 1996), and anti-endotoxin therapies (Antimicrob Agents Chemother 1989; J Clin Invest 1987; Pharm Res 1990; JAMA 1993; J Infect Dis 1994). Nitric oxide (NO) was investigated in septic shock (Crit Care Med 1993; JAMA 1996). Non-selective NO synthase inhibitors were toxic or lacked benefit (J Exp Med 1992; Crit Care Med 1998; Am J Respir Crit Care Med 1998). NO in LPS-challenged volunteers was blocked by ibuprofen, but BP was unaffected (J Pharmacol Exp Ther 1999). Risk of death affected the therapeutic efficacy of anti-inflammatory agents in sepsis (Am J Respir Crit Care Med 2002). L-arginine in canine septic shock was harmful (Crit Care Med 2006). Our canine sepsis model was redeveloped to balance animal welfare and relevance (Am J Physiol Heart Circ Physiol 2007). Risk of death and hydrocortisone efficacy were investigated in a mouse pneumonia model (Intensive Care Med 2008). Intra-aortic balloon counterpulsation prolonged survival in canine Staphylococcal pneumonia-induced septic shock (Crit Care Med 2009). The U.S. Critical Illness and Injury Trials Group (USCIITG; http://www.usciitg.org/) was founded (Crit Care Med 2009). Septic shock survival was associated with early and appropriate antibiotics (Crit Care Med 2010). Inhibiting p38 improved cardiac function but worsened lung injury and survival in murine pneumonia (J Trauma 2010). Fluids and vasopressors were harmful in a rat model of anthrax lethal toxin (LeTx; Crit Care Med 2009). In canines, edema toxin increased mortality when added to LeTx (J Infect Dis 2010). Heparin failed to improve lung injury or survival in E. coli pneumonia (Crit Care Med 2011). In canine pneumonia, mineralocorticoid was beneficial prophylactically, while glucocorticoid was beneficial at the onset of infection (Crit Care Med 2012). Corticosteroids were beneficial in sepsis with a high risk of death (Intensive Care Med 2012). Tigecycline was associated with increased mortality (Clin Infect Dis 2012). Colistin use identified a severely ill population with drug-resistant bacteria (Clin Infect Dis 2015). Using an aerosolized staphylococcal enterotoxin B (SEB) mouse model, gene-expression changes implicated a multiorgan IFN-response (PLoS One 2014). HPA unresponsiveness and aldosterone levels were associated with poor outcomes in canine pneumonia (Am J Physiol Endocrinol Metab 2014). SUPPORT consent forms incorrectly characterized the low oxygen saturation arm as usual care (PLoS One 2016). Toxoplasmosis encephalitis was complicated by IRIS in an allogeneic stem cell transplant patient (Bone Marrow Transplant 2016). Meningoencephalitis was characterized in Ebola (Ann Intern Med 2016). Diagnosing sepsis is subjective and variable (Critical Care 2016). Septic shock incidence and mortality changed less than previously estimated (Chest 2017). In necrotizing fasciitis and shock, IVIG failed to decrease mortality (Clin Infect Dis 2017). Sepsis incidence and death rate was stable between 2009-2014 (JAMA 2017). Low dose alteplase for submassive pulmonary embolism might be useful in selected patients (Blood Coagul Fibrinolysis 2018). Meta-analysis of restrictive vs. liberal transfusion in patients with cardiovascular disease demonstrated an increased risk of death and coronary events (Transfusion Med 2018). Difficult to Treat Resistance (DTR) in gram-negative bloodstream infections was an independent contributor to death (Clin Infect Dis 2018; Open Forum Infect Dis 2019). Variation in the accuracy of claims data for sepsis and organ dysfunction limited their usefulness (Crit Care Med 2019). Using tracer antibiotic algorithms, attributable mortality for XDR gram-negative infections varied by comparator agents and patient characteristics (Am J Infect Control 2019). In a meta-analysis of PCT-guided antibiotic discontinuation, benefit was only seen in low quality studies with poor adherence (Chest 2019). In patients with community-onset sepsis, both inadequate and unnecessarily broad empiric antibiotics were associated with mortality (JAMA Netw Open 2020). Measures have been inadequate to ensure that subjects in comparative effectiveness trials are receiving usual and not unusual care (Crit Care Resusc 2020). The rarity of GNIs with no or suboptimal treatment options underscores the necessity for non-revenue-based strategies and innovative trial designs (Lancet Infect Dis 2020). Ceftazidime-avibactam use has increased, while colistin has correspondingly declined (Clin Infect Dis 2021). One in 5 patients with BSIs in US hospitals received discordant empirical antibiotic therapy, which was associated with mortality. Early identification of resistant pathogens will likely improve population-level outcomes (Lancet Infect Dis 2021). Clindamycin improves the outcome of invasive group A-hemolytic streptococcal, but not non-group A/B-hemolytic streptococcal infections (Lancet Infect Dis 2021). Cell-free hemoglobin adversely impacts sepsis outcomes through more than one mechanism and could represent a novel therapeutic target (Am J Physiol Heart Circ Physiol 2021). Despite improvements in COVID-19 survival, surges in hospital caseloads were detrimental to survival. Bolstering prevention to suppress surges and better support for surging hospitals may save lives (Ann Intern Med 2021). In an inpatient and outpatient study, SARS-CoV-2 healthcare burden and illness severity were similar between index and reinfection encounters (Clin Infect Dis 2022). Among patients with S maltophilia infections, levofloxacin (n = 823) displayed statistically similar mortality risk compared to TMP-SMX (n = 758) (Open Forum Infect Dis 2022). One-third of critical care comparative effectiveness research (CER) trials published in premier journals did not include a designated control arm representative of contemporary practices. Failure to incorporate contemporary practices into critical care CER trials is a widespread design weakness (Crit Care Resusc 2022). Severe COVID-19 is associated with multiorgan failure and small vessel vasculopathy with microthrombi. However, antiplatelet therapy (Ann Intern Med commentary 2022) and aggressive anticoagulation have not improved outcome. We are examining endothelial senescence as a targetable mechanism of COVID-19 vasculopathy. Septic shock results in ventricular wall changes not explained by loading or myocardial necrosis (ACC abstract 2022). LVEF depression was not exacerbated by early EPI, rather EPI appeared cardioprotective (ACC 2022). Sepsis-induced cardiac injury was associated with edema by histopathology and CMRI (ACC abstract 2022). Acute LV dry mass loss occurred as edema increased and EF recovered, consistent with an adaptive, reparative process. Determining how dry mass is lost may clarify mechanisms of cardiac injury and repair in septic shock (AHA abstract 2023). Procalcitonin (PCT)-on-admission demonstrated poor sensitivity in ruling out BSI and did not appear to meaningfully alter empiric antibiotic usage. Diagnostic and decision-making stewardship of PCT-on-admission is warranted (Crit Care Med. 2023). Flawed critical care CER trial designs can lead to unsound conclusions, compromise informed consent, increase risks to research subjects, and undermine the goal of informing current practice. Well-constructed control and comparator arms are indispensable elements of critical care CER trials (Clin Trials 2023, in press).
期刊论文(19)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s12281-015-0219-0
发表时间: 2015-06
期刊: Current fungal infection reports
影响因子: 1.4
作者: [Moriyama B, Kadri S, Henning SA, Danner RL, Walsh TJ, Penzak SR]
通讯作者: Penzak SR
DOI: 10.1097/ccm.0b013e3181cb0ddf
发表时间: 2010-02
期刊: Critical care medicine
影响因子: 8.8
作者: [Barochia AV, Cui X, Vitberg D, Suffredini AF, O'Grady NP, Banks SM, Minneci P, Kern SJ, Danner RL, Natanson C, Eichacker PQ]
通讯作者: Eichacker PQ
Persistence of Pseudomonas aeruginosa in a pulmonary nodule with late relapse.
肺结节中铜绿假单胞菌的持续存在,且晚期复发。
DOI: 10.1111/tid.12253
发表时间: 2014
期刊: Transplant infectious disease : an official journal of the Transplantation Society
影响因子: --
作者: [Ronkainen,S, Xie,Y, Battiwalla,M, Barrett,AJ, Stock,F, Dekker,JP, Danner,RL]
通讯作者: Danner,RL
ACP Journal Club: review: in sepsis, the effect of resuscitation with crystalloid and colloid fluids on mortality varies.
ACP 期刊俱乐部:评论:在脓毒症中,晶体液和胶体液复苏对死亡率的影响各不相同。
DOI: 10.7326/0003-4819-161-10-201411180-02012
发表时间: 2014
期刊: Annals of internal medicine
影响因子: 39.2
作者: [Kadri,SameerS, Danner,RobertL]
通讯作者: Danner,RobertL
共 8 条
    Functional Genomics Of Critical Illness
    • 批准号:
      6825020
    • 项目类别:
    • 资助金额:
      $0.0万
    • 财政年份:
      --
    • 负责人:
      ROBERT L DANNER
    • 依托单位:
    Functional Genomics Of Critical Illness
    • 批准号:
      7212416
    • 项目类别:
    • 资助金额:
      $0.0万
    • 财政年份:
      --
    • 负责人:
      ROBERT L DANNER
    • 依托单位:
    Preclinical and Clinical Investigations in Septic Shock
    • 批准号:
      7215797
    • 项目类别:
    • 资助金额:
      $0.0万
    • 财政年份:
      --
    • 负责人:
      ROBERT L DANNER
    • 依托单位:
    Nitric Oxide Regulation of Inflammatory Responses and Gene Expression
    • 批准号:
      8952789
    • 项目类别:
    • 资助金额:
      $0.0万
    • 财政年份:
      --
    • 负责人:
      ROBERT L DANNER
    • 依托单位:
    海外基金